Biotest Aktiengesellschaft (ETR:BIO)
Germany
· Delayed Price · Currency is EUR 40.80
0.00 (0.00%)
Mar 28, 2025, 5:36 PM CET
ETR:BIO Revenue
Biotest Aktiengesellschaft had revenue of 150.70M EUR in the quarter ending September 30, 2024, a decrease of -33.02%. This brings the company's revenue in the last twelve months to 707.00M, up 7.84% year-over-year. In the year 2023, Biotest Aktiengesellschaft had annual revenue of 684.60M with 32.65% growth.
Revenue (ttm)
707.00M
Revenue Growth
+7.84%
P/S Ratio
n/a
Revenue / Employee
291.43K
Employees
2,426
Market Cap
1.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 684.60M | 168.50M | 32.65% |
| Dec 31, 2022 | 516.10M | 500.00K | 0.10% |
| Dec 31, 2021 | 515.60M | 31.40M | 6.48% |
| Dec 31, 2020 | 484.20M | 65.10M | 15.53% |
| Dec 31, 2019 | 419.10M | 18.80M | 4.70% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.16B |
| Siemens Healthineers AG | 22.67B |
| Fresenius SE & Co. KGaA | 21.83B |
| Bayer Aktiengesellschaft | 46.61B |
| Sartorius Aktiengesellschaft | 3.38B |
| Fresenius Medical Care AG | 19.34B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.16B |
Biotest Aktiengesellschaft News
- 25 days ago - EQS-Adhoc: Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future. - Wallstreet:Online
- 4 weeks ago - Biotest AG's Preliminary Results Surpass 2024 Forecasts! - Wallstreet:Online
- 4 weeks ago - EQS-Adhoc: Biotest AG publishes preliminary business figures - 2024 forecasts partially exceeded - Wallstreet:Online
- 2 months ago - Biotest's Big Step: FDA Review for Fibrinogen Biologics - Wallstreet:Online
- 2 months ago - EQS-News: Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) - Wallstreet:Online
- 4 months ago - EQS-News: Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations - Wallstreet:Online
- 4 months ago - Biotest Boosts Revenue by 4.5% to €523M in First 9 Months! - Wallstreet:Online
- 4 months ago - EQS-News: Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million - Wallstreet:Online